TABLE 1.
Oligonucleotides used in this studya
| Primer | 5′-3′ sequence |
|---|---|
| ENA1-ATG | TCAGTTCAAGACAGCAGGTTCATC |
| ENA1-STOP | GCTACAGTGTGCTATGAAAGAAAG |
| XbaI-ENA2-ATG | GTCTAGATAAACAATGGTTCACGGTCATGGCT |
| ENA2-STOP | TGGCAGGACGGGGAGACGCAATAC |
| NdeI-ENA1ATG | CCATATGGTGCACAAGAAAGAAGACAAG |
| NdeI-ENA1Rev | CCATATGTTTCACCATCGTTTTCTCGGTCGAGG |
| BamHI-ENA2ATG | GGGATCCTAAACAATGGTTCACGGTCATGGCT |
| NdeI-ENA2Rev | CCATATGTCTAGCAGTGGCGGCCGACTTTTC |
| PC-13B8-1 | GGACACCTGGGGGAAGAACAAG |
| PC-13B8-1R | GGCCGGTGCAGACGAAGATGAT |
| PC-14G4-2 | CTTTCATTGCCGTGGTCGAGCTGT |
| PC-14G4-2R | TTTTCGCTCAGTTGCTTCTTCGCC |
| UmACT1-2 | GTGCCCATCTACGAAGGTTACT |
| UmACT1-1R | CGGCAGTGGTGGTGAAGGGGTAG |
| XbaNcENA2-ATG | GTCTAGAAAACAATGGGGACAGAGATCGAACTT |
| NcENA2-STOP | TTCTTACACACCCTCTCCACCAACC |
| Bam-NcENA2Rev | CGGATCCTGTACACACCCTCTCCACCAACC |
a
In some of the primers, a restriction site sequence was included (underlined).